The latest coronavirus variant called Omicron continues to make headlines all over the place. Even though the symptomatology is not that severe in the case of Omicron, its contagiousness is pretty high. Check out the latest reports about this new variant of the virus below.
Live Mint reveals that with Omicron BA.2 dethroning previously identified BA.1 subvariant, questions regarding reinfection are looming large.
The publication notes the fact that a new Danish study has recently revealed that it is not impossible to get infected with two sub-variants of Omicron, but the chances are rare.
It’s been also revealed that the researchers also suggested the virus load would be less the second time considering the patient is likely to develop immunity the first time.
The new study was led by researchers at Denmark’s top infectious disease authority, Statens Serum Institut (SSI). But it’s also important to note that the study is yet to be peer-reviewed.
“We provide evidence that Omicron BA.2 reinfections are rare but can occur relatively shortly after a BA.1 infection,” the study authors said.
Experts added that the reinfections mostly affected young, unvaccinated individuals and only caused mild disease, none of which led to hospitalizations or deaths.
India rejects Pfizer
In other recent news, it’s been revealed that Pfizer has been making headlines in 2022 just like during the previous year, due to their covid vaccines and treatments against the disease triggered by the novel coronavirus. Check out the latest reports coming from India and revealing something pretty interesting about the vaccine policies over there.
Check out this relevant Twitter post.
India’s drug regulators have effectively declined Pfizer’s COVID vaccine emergency use approval, citing an ongoing investigation into side effects reported in other countries.
As a result, the vaccine won’t be available in the country.
This is a great win for medical integrity. pic.twitter.com/pmOovMTOwi
— Dr. Simone Gold (@drsimonegold) February 22, 2022
Stay tuned for more news.